Bullboard - Stock Discussion Forum COMPASS Pathways Plc CMPS

Healthcare Biotechnology

Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in the development of psilocybin treatment, in which its investigational COMP360 psilocybin is administered in conjunction with psychological support, COMP360 psilocybin treatment. COMP360 is its proprietary... see more

Add To Watchlist

NDAQ:CMPS - Post Discussion

COMPASS Pathways Plc > CMPS Q3 2020 Financial Results

View:

Post by PsilocybinAlpha on Nov 12, 2020 7:22am

CMPS Q3 2020 Financial Results

Third quarter and post-period highlights:

Completed upsized initial public offering (IPO) on Nasdaq, raising $146.6 million
Continued to progress phase IIb clinical trial of COMP360 psilocybin therapy for treatment-resistant depression
Strengthened board and leadership team with appointments of Linda McGoldrick as non-Executive Director; Greg Ryslik as Senior Vice President, Data Science, Machine Learning and Digital Health Research; and Stephen Schultz as Senior Vice President, Investor Relations
Established Drug Discovery Center with the University of the Sciences in Philadelphia, PA
Conference call today at 1.00pm GMT (8.00am ET)